525 related articles for article (PubMed ID: 17634143)
1. Multiple myeloma/hypercalcemia.
Oyajobi BO
Arthritis Res Ther; 2007; 9 Suppl 1(Suppl 1):S4. PubMed ID: 17634143
[TBL] [Abstract][Full Text] [Related]
2. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).
Giuliani N; Colla S; Rizzoli V
Exp Hematol; 2004 Aug; 32(8):685-91. PubMed ID: 15308315
[TBL] [Abstract][Full Text] [Related]
3. Evidence of a role for RANKL in the development of myeloma bone disease.
De Leenheer E; Mueller GS; Vanderkerken K; Croucher PI
Curr Opin Pharmacol; 2004 Aug; 4(4):340-6. PubMed ID: 15251126
[TBL] [Abstract][Full Text] [Related]
4. [Hypercalcemia in myeloma].
Abe M
Nihon Rinsho; 2007 Dec; 65(12):2245-9. PubMed ID: 18069268
[TBL] [Abstract][Full Text] [Related]
5. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI
Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of bone destruction in multiple myeloma.
Terpos E; Christoulas D; Gavriatopoulou M; Dimopoulos MA
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28940410
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy.
Oyajobi BO; Anderson DM; Traianedes K; Williams PJ; Yoneda T; Mundy GR
Cancer Res; 2001 Mar; 61(6):2572-8. PubMed ID: 11289133
[TBL] [Abstract][Full Text] [Related]
8. Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease.
Oyajobi BO; Franchin G; Williams PJ; Pulkrabek D; Gupta A; Munoz S; Grubbs B; Zhao M; Chen D; Sherry B; Mundy GR
Blood; 2003 Jul; 102(1):311-9. PubMed ID: 12649140
[TBL] [Abstract][Full Text] [Related]
9. Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma.
Heider U; Langelotz C; Jakob C; Zavrski I; Fleissner C; Eucker J; Possinger K; Hofbauer LC; Sezer O
Clin Cancer Res; 2003 Apr; 9(4):1436-40. PubMed ID: 12684416
[TBL] [Abstract][Full Text] [Related]
10. Update on the pathogenesis of osteolysis in multiple myeloma patients.
Giuliani N; Colla S; Rizzoli V
Acta Biomed; 2004 Dec; 75(3):143-52. PubMed ID: 15796087
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of bone lesions in multiple myeloma and lymphoma.
Roodman GD
Cancer; 1997 Oct; 80(8 Suppl):1557-63. PubMed ID: 9362422
[TBL] [Abstract][Full Text] [Related]
12. Evidence for the secretion of an osteoclast stimulating factor in myeloma.
Mundy GR; Raisz LG; Cooper RA; Schechter GP; Salmon SE
N Engl J Med; 1974 Nov; 291(20):1041-6. PubMed ID: 4413338
[No Abstract] [Full Text] [Related]
13. Relation of osteoclast activating factor production to extent of bone disease in multiple myeloma.
Durie BG; Salmon SE; Mundy GR
Br J Haematol; 1981 Jan; 47(1):21-30. PubMed ID: 7437344
[TBL] [Abstract][Full Text] [Related]
14. [Bone hyperresorption in multiple myeloma].
Beaudreuil J; Orcel P
Presse Med; 2000 Mar; 29(9):492-7. PubMed ID: 10745943
[TBL] [Abstract][Full Text] [Related]
15. [Mechanisms for formation of myeloma bone disease].
Yata K; Abe M; Matsumoto T
Clin Calcium; 2008 Apr; 18(4):438-46. PubMed ID: 18379024
[TBL] [Abstract][Full Text] [Related]
16. Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma.
Oyajobi BO; Mundy GR
Cancer; 2003 Feb; 97(3 Suppl):813-7. PubMed ID: 12548580
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
Croucher PI; Shipman CM; Van Camp B; Vanderkerken K
Cancer; 2003 Feb; 97(3 Suppl):818-24. PubMed ID: 12548581
[TBL] [Abstract][Full Text] [Related]
18. The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy.
Morony S; Warmington K; Adamu S; Asuncion F; Geng Z; Grisanti M; Tan HL; Capparelli C; Starnes C; Weimann B; Dunstan CR; Kostenuik PJ
Endocrinology; 2005 Aug; 146(8):3235-43. PubMed ID: 15845617
[TBL] [Abstract][Full Text] [Related]
19. Significance of parathyroid hormone-related protein as a factor stimulating bone resorption and causing hypercalcemia in myeloma.
Tsujimura H; Nagamura F; Iseki T; Kanazawa S; Saisho H
Am J Hematol; 1998 Oct; 59(2):168-70. PubMed ID: 9766803
[TBL] [Abstract][Full Text] [Related]
20. [High PTHrP level induced hypercalcemia and acute renal failure in a multiple myeloma patient].
Saito O; Kurosu M; Ando Y; Kusano E; Asano Y
Nihon Jinzo Gakkai Shi; 2000 Jan; 42(1):41-6. PubMed ID: 10737013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
